Postoperative radiotherapy does not improve survival in patients with Masaoka-Koga stage IIB thymomas: A propensity score matching study based on the SEER database

• Published in: Medicine (Baltimore) 2024-05, Vol.103 (19), p.e37956-e37956
• Main Authors: Shi, Yonggang, Chen, Heng, Luo, Shengbo, Xiong, Jianwen, Xiong, Linmin, Yu, Dongliang
• Format: Article
• Language: English
• Subjects: Adult; Aged; Female; Humans; Male; Middle Aged; Neoplasm Staging; Observational Study; Prognosis; Propensity Score; Radiotherapy, Adjuvant; Retrospective Studies; SEER Program; Survival Rate; Thymoma - mortality; Thymoma - pathology; Thymoma - radiotherapy; Thymoma - surgery; Thymus Neoplasms - mortality; Thymus Neoplasms - pathology; Thymus Neoplasms - radiotherapy; Thymus Neoplasms - surgery
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000037956

This study, based on a population, explored the prognostic value of postoperative radiotherapy (PORT) for Masaoka-Koga IIB stage thymomas. Patients diagnosed with thymoma from 2004 to 2017 in the Surveillance, Epidemiology, and End Results (SEER) database were included in the retrospective study. Through propensity score matching, the baseline characteristics of the patients were successfully matched to mitigate the selection bias of PORT. Survival rates and survival curves were compared between the PORT and non-PORT groups, with potential confounding factors addressed using a multivariate Cox regression model. In this study, 785 cases of IIB stage thymoma were included from the SEER database, and 303 patients were successfully matched between PORT and non-PORT groups through propensity score matching, with no significant differences in baseline characteristics. In the PORT and non-PORT groups, 10-year overall survival rates were 65.2% versus 59.6%, and cancer-specific survival rates were 87.0% vs. 84.4%, PORT did not yield statistically significant improvements in overall survival (P = .275) or cancer-specific survival (P = .336) for stage IIB thymomas. Based on the SEER database, the results of our study indicated that PORT does not confer a significant survival benefit for IIB stage thymomas.